Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: Reuters Investment Profile
Provider: Pechala's Reports
Provider: Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AstraZeneca PLC Collaborates With FibroGen On Anaemia Treatment

Wednesday, 31 Jul 2013 02:00am EDT 

AstraZeneca PLC and FibroGen announced that they have entered into a strategic collaboration to develop and commercialise FG-4592, am oral compound in late stage development for the treatment of anaemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD). The AstraZeneca-FibroGen joint effort will be focused on the development of FG-4592 to treat anaemia in CKD and ESRD, and may be extended to other anaemia indications. 

Company Quote

30.0 +0.64%
21 Nov 2014